- Home
- XGN vs ONCY Comparison
XGN vs ONCY Comparison
Compare XGN & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- ONCY
- Stock Information
- Founded
- XGN 2002
- ONCY 1998
- Country
- XGN United States
- ONCY Canada
- Employees
- XGN N/A
- ONCY N/A
- Industry
- XGN Medical Specialities
- ONCY Pharmaceuticals and Biotechnology
- Sector
- XGN Health Care
- ONCY Health Care
- Exchange
- XGN Nasdaq
- ONCY Nasdaq
- Market Cap
- XGN 72.3M
- ONCY 86.1M
- IPO Year
- XGN 2019
- ONCY 1999
- Fundamental
- Price
- XGN $5.65
- ONCY $0.76
- Analyst Decision
- XGN Buy
- ONCY Strong Buy
- Analyst Count
- XGN 1
- ONCY 2
- Target Price
- XGN $7.00
- ONCY $4.00
- AVG Volume (30 Days)
- XGN 189.6K
- ONCY 359.4K
- Earning Date
- XGN 11-12-2024
- ONCY 11-12-2024
- Dividend Yield
- XGN N/A
- ONCY N/A
- EPS Growth
- XGN N/A
- ONCY N/A
- EPS
- XGN N/A
- ONCY N/A
- Revenue
- XGN $55,751,000.00
- ONCY N/A
- Revenue This Year
- XGN $6.74
- ONCY N/A
- Revenue Next Year
- XGN $17.32
- ONCY N/A
- P/E Ratio
- XGN N/A
- ONCY N/A
- Revenue Growth
- XGN 8.00
- ONCY N/A
- 52 Week Low
- XGN $1.30
- ONCY $0.76
- 52 Week High
- XGN $6.22
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- XGN 74.82
- ONCY 26.96
- Support Level
- XGN $5.60
- ONCY $0.91
- Resistance Level
- XGN $6.22
- ONCY $0.88
- Average True Range (ATR)
- XGN 0.48
- ONCY 0.04
- MACD
- XGN 0.13
- ONCY -0.01
- Stochastic Oscillator
- XGN 88.00
- ONCY 11.12
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.